Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | PPARD | Q03181 | 7/20 | 0.39 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049103 | 1.00 | GPR84 (0.39) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL10937554 | 1.00 | GPR84 (0.39) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL2053235 | 0.98 | AKR1B1 (0.37) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL14714718 | 0.90 | TERT (0.49) | PPARGPPARDPPARAPTPN1TDP1 | |
| SCHEMBL278015 | 0.83 | TSHR (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL250704 | 0.83 | TSHR (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL251265 | 0.83 | TSHR (0.44) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL2946123 | 0.82 | EPHX2 (0.35) | — | |
| SCHEMBL9518086 | 0.81 | CES2 (0.38) | FABP3 | |
| SCHEMBL250482 | 0.81 | LMNA (0.42) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382868-B2 | Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same | ICURE PHARMACEUTICAL INC. (KR) | 2022-07-12 | — | — | US | claimed |
| EP-2687205-B1 | FENTANYL TRANSDERMAL PATCH | ICURE PHARMACEUTICAL CORP (KR) | 2020-12-23 | — | — | EP | claimed |
| US-20190091168-A1 | FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG | UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) | 2019-03-28 | — | — | US | claimed |
| US-20190046463-A1 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME | ICURE PHARMACEUTICAL INC. (KR) | 2019-02-14 | — | — | US | claimed |
| EP-3415141-A1 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME | Icure Pharmaceutical Inc. (KR) | 2018-12-19 | — | — | EP | claimed |
| US-9295655-B2 | Fentanyl transdermal patch | ICURE (KR) | 2016-03-29 | — | — | US | claimed |
| CN-102946873-B | percutaneous absorption preparation | ICURE PHARM INC | 2015-05-13 | — | — | CN | claimed |
| EP-2687205-A2 | FENTANYL TRANSDERMAL PATCH | Icure Pharmaceutical Corp. (KR) | 2014-01-22 | — | — | EP | claimed |
| US-20140005617-A1 | FENTANYL TRANSDERMAL PATCH | ICURE (KR) | 2014-01-02 | — | — | US | claimed |
| US-20130165875-A1 | TRANSDERMAL ABSORPTION PREPARATION | ICURE PHARMACEUTICAL INC. (KR) | 2013-06-27 | — | — | US | claimed |
| EP-2561865-A2 | TRANSDERMAL ABSORPTION PREPARATION | Icure Pharmaceutical Inc. (KR) | 2013-02-27 | — | — | EP | claimed |
| CN-102946873-A | Percutaneous absorption preparation | ICURE PHARM INC | 2013-02-27 | — | — | CN | claimed |
| JP-4271869-B2 | — | — | 2009-06-03 | — | — | JP | claimed |
| JP-2002536412-A | — | — | 2002-10-29 | — | — | JP | claimed |
| EP-1150675-A1 | A TRANSDERMAL COMPOSITION OF AN ANTIVOMITING AGENT AND A PREPARATION CONTAINING THE SAME | Samyang Corporation (KR) | 2001-11-07 | — | — | EP | claimed |
| WO-2000047208-A1 | A TRANSDERMAL COMPOSITION OF AN ANTIVOMITING AGENT AND A PREPARATION CONTAINING THE SAME | SAMYANG CORPORATION (KR) | 2000-08-17 | — | — | WO | claimed |
| CN-114129544-B | Ultraviolet curable hydrogel resin for transdermal administration, hydrogel, and cataplasm comprising same | Icure药品株式会社 | 2025-03-21 | — | — | CN | disclosed |
| WO-2023106506-A1 | HYDROGEL COMPOSITION FOR PREPARING TRANSDERMAL PATCH COMPRISING AMPHIPHILIC POLYMER ADHESIVE, AND TRANSDERMAL PATCH USING SAME | 주식회사 이엘와이컴퍼니 | 2023-06-15 | — | — | WO | disclosed |
| EP-1150675-A1 | A TRANSDERMAL COMPOSITION OF AN ANTIVOMITING AGENT AND A PREPARATION CONTAINING THE SAME | Samyang Corporation (KR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047208-A1 | A TRANSDERMAL COMPOSITION OF AN ANTIVOMITING AGENT AND A PREPARATION CONTAINING THE SAME | SAMYANG CORPORATION (KR) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091168-A1 | FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG | APP, PSEN2, PSEN1 | GPR84 3121/4885PPARG 128/4885PPARD 54/4885 |
| US-20140005617-A1 | FENTANYL TRANSDERMAL PATCH | CD69, OPRD1, OPRL1 | GPR84 307/4885PPARG 2815/4885PPARD 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.